Benefits persist for lenvatinib, pembrolizumab in renal cell cancer (And not for sunitinib)

Medical Xpress / HealthDay / The Lancet Oncology ^ | March 13, 2023 | Elana Gotkine / Toni K Choueiri et al

[ConservativeMind]

For patients with advanced renal cell carcinoma, progression-free survival and overall survival are improved with lenvatinib plus pembrolizumab versus sunitinib, according to a study.

Toni K. Choueiri, M.D. and colleagues conducted a protocol-prespecified updated overall survival analysis of the phase 3 CLEAR trial. Patients with clear-cell advanced renal cell carcinoma who had not received any systemic anticancer therapy were eligible and randomly assigned to receive lenvatinib plus pembrolizumab, lenvatinib plus everolimus, or sunitinib (355, 357, and 357, respectively). This updated analysis did not report on patients in the lenvatinib plus everolimus group.

The median follow-up for progression-free survival was 27.8 and 19.4 months in the lenvatinib plus pembrolizumab group and the sunitinib group, respectively. The researchers found that median progression-free survival was 23.3 and 9.2 months in the lenvatinib plus pembrolizumab group and sunitinib group, respectively (stratified hazard ratio, 0.42). For overall survival, median follow-up was 33.7 and 33.4 months in the lenvatinib plus pembrolizumab group and sunitinib group, respectively; overall survival was improved with lenvatinib plus pembrolizumab versus sunitinib (hazard ratio, 0.72).

"This extended follow-up analysis shows the durable and clinically meaningful efficacy benefit with lenvatinib plus pembrolizumab over sunitinib," the authors write. "Previously observed benefits in overall survival, progression-free survival, and objective response rate were maintained."

[ConservativeMind]

Sunitinib appears to be the worst of the choices.

Lenvatinib and pembrolizumab are both available, today.

[ConservativeMind]

The “Take Charge Of Your Health” Ping List
This high volume ping list is for health articles and studies which describe something you or your doctor, when informed, may be able to immediately implement for your benefit.

Email me to get on either the “Common/Top Issues” (20 - 25% fewer pings) or “Everything” list.

[TermLimits4All]

This is what my father died of. He allowed the University of Michigan to do experimental testing on him in the 90s, he lasted all of a year after diagnosis. Or a year after actually telling us he had cancer. I hope that research is helping others.
If I recall the were giving him Interleuken 2. I remember visiting him at the hospital and he would be having convulsions. Not a good thing for a kid to see.